Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16629746 | 0.86 | LMNA (0.49) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL14597535 | 0.80 | CA1 (0.46) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL21048453 | 0.74 | KMT2A (0.68) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL16829044 | 0.74 | KMT2A (0.68) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL5806483 | 0.72 | KMT2A (0.67) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL5806478 | 0.72 | KMT2A (0.67) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL23796372 | 0.72 | KMT2A (0.51) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL3510634 | 0.71 | KMT2A (0.51) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL3510632 | 0.71 | KMT2A (0.51) | KMT2ATSHRHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL20777777 | 0.71 | EPHX2 (0.42) | KMT2ATSHRHSD17B10ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-02 | — | — | US | disclosed |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-16 | — | — | US | disclosed |
| US-11713304-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-01 | — | — | US | disclosed |
| US-20220135536-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-05 | — | — | US | disclosed |
| EP-3532468-B1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AG (DE) | 2022-03-23 | — | — | EP | disclosed |
| US-9486448-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486448-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2015050798-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713304-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | KMT2A 2263/4885TSHR 3994/4885HSD17B10 97/4885 |
| US-20220135536-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DHPS, DPYD | KMT2A 2263/4885TSHR 3994/4885HSD17B10 97/4885 |
| US-12486248-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DHPS, DPYD | KMT2A 2263/4885TSHR 3994/4885HSD17B10 97/4885 |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KMT2A 4197/4885TSHR 342/4885HSD17B10 2611/4885 |
| US-20230365524-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DHPS, DPYD | KMT2A 2263/4885TSHR 3994/4885HSD17B10 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.